Stem Cells and Cell Therapies in Lung Biology and Diseases

描述(申请人提供)：干细胞和细胞疗法在肺生物学和疾病中使用干细胞修复和再生患病的肺是一种令人兴奋的潜在治疗方法，可用于各种肺部疾病。越来越多的信息表明，正常情况下不在肺内的细胞可以用来损伤肺损伤，也可以诱导损伤后的修复和重塑。与此同时，研究使用人工和去细胞肺基质作为三维肺再生框架的生物工程研究激增。将这些研究与那些利用干细胞和/或细胞疗法的研究相结合，是一个很有前途的快速发展方向。与这些研究进一步平行的是，人们对驻留在肺中的干细胞和/或祖细胞参与肺发育以及肺损伤后修复和重塑的分子和细胞事件的了解显著增加。我们之前已经在佛蒙特大学举办了四次会议：2005年7月，由NHBLI和囊性纤维化基金会赞助的“成人干细胞、肺生物学和肺部疾病”；2007年7月、2009年和2011年7月，由NHLBI通过R13会议赠款赞助，以及由Alpha 1抗胰酶基金会、埃默里呼吸健康中心、LAM治疗联盟、肺纤维化基金会和佛蒙特州大学医学院赞助。这些会议聚集了相关的领先国际研究人员以及感兴趣的初级教职员工和实习生进行辩论和讨论。 在这个快速变化的领域中的问题。这些会议非常成功，既激励了这一领域，也产生了一系列关于基础和翻译研究的准则，供调查人员和供资机构使用。随着干细胞和细胞疗法治疗肺部疾病的研究继续快速发展，我们建议再次召集相关调查人员以及来自NHLBI、FDA和非营利性呼吸系统疾病基金会的代表再次辩论和讨论当前的问题。特别要讨论的一个领域是基础研究和转化性研究之间的平衡以及临床试验的作用，特别是因为现在已经有干细胞治疗肺动脉高压和慢性阻塞性肺病的临床试验。即将举行的会议的一个特别重点将是正在崛起的初级调查员和受训人员，一个新的特点将是专门讨论这一领域的职业发展的会议。与往常一样，Junor调查人员和受训人员(研究生、博士后、研究员)将特别有针对性地被纳入会议讨论和招贴会议。作为一个持续的特点，学员将能够通过盲目审查海报摘要来竞争更多的旅行奖项。会议计划于2013年7月在佛蒙特州大学举行。潜在参与者的热情很高。我们预计这次会议将再次促进广泛的讨论和辩论，并将显著指导干细胞和肺部疾病细胞疗法的基础和临床研究方向。

DESCRIPTION (provided by applicant): Stem Cells and Cell Therapies in Lung Biology and Diseases Repair and regeneration of diseased lung with stem cells is an exciting potential therapeutic approach for a variety of lung diseases. Increasing information suggests that cells normally not resident in the lung can be utilized to impair lung injry and also to induce repair and remodeling after injury. In parallel, there has been a surge in bioengineering studies investigating use of artificial and de-cellularized lung matrices as framework for three-dimensional lung regeneration. The combination of these studies with those utilizing stem cells and/or cell therapies is a promising and rapidly developing direction. These studies have been further paralleled by significant increases in understanding the molecular and cellular events by which stem and/or progenitor cells resident in the lung participate in both lung development and in repair and remodeling after lung injury. We have held four previous conferences at the University of Vermont: July 2005, "Adult Stem Cells, Lung Biology, and Lung Disease", sponsored by the NHBLI and Cystic Fibrosis Foundation~ and in July 2007, 2009, and 2011 "Stem Cells and Cell Therapies in Lung Biology and Disease", sponsored through the years by the NHLBI through an R13 conference grant as well as by the Alpha 1 Antitrypsin Foundation, Emory Center for Respiratory Health, LAM Treatment Alliance, Pulmonary Fibrosis Foundation, and the University of Vermont College of Medicine. These conferences have that brought together relevant leading international investigators as well as interested junior faculty and trainees to debate and discuss issues in this rapidly moving field. These conferences have been highly successful and have both stimulated the field and resulted in a series of guidelines for basic and translation research to be utilized by both investigators and by funding agencies. As studies of stem cell and cell therapies for lung diseases continues to move at a rapid pace, we propose to again convene the relevant investigators as well as representatives from the NHLBI, FDA, and non-profit Respiratory Disease Foundations to again debate and discuss current issues. One area in particular to be discussed is the balance between basic and translational research and the role of clinical trials, particularly as there have now been clinica trials of stem cells for pulmonary hypertension and for COPD. A particular focus for the upcoming conference will be on rising junior investigators and trainees and a new feature will be a session devoted to developing careers in this area. As always, junor investigators and trainees (graduate, post-doctoral, fellow) will be particularly targeted for inclusion in both conference discussions as well as in poster sessions. As a continuing feature, trainees will be able to compete for an increased number of travel awards based on blinded review of poster abstracts. The conference is planned for July 2013 at the University of Vermont. Enthusiasm is high among potential participants. We anticipate that this conference will again foster extensive discussion and debate and will significantly guide directions in basic and clinical research of stem cells and cell therapies for lung diseases.